Palatin Technologies (PTN) Cash from Financing Activities (2010 - 2026)
Palatin Technologies' (PTN) quarterly Cash from Financing Activities came in at $138878.0 in Q1 2026, down 96.88% YoY from $4.5 million in Q1 2025, and down 99.23% on a QoQ basis from $18.0 million in Q4 2025.
Palatin Technologies (PTN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Cash from Financing Activities data on file, last reported at $138878.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 96.88% year-over-year to $138878.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.0 million (up 60.52% YoY) and the FY2025 annual result came in at $11.2 million, down 45.43% from the prior year.
- Cash from Financing Activities eased to $138878.0 in Q1 2026, from $18.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $18.0 million in Q4 2025 to a low of -$126969.0 in Q3 2024.
- A 5-year average of $3.6 million and a median of $1.0 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 705.64% — and 2024, when it soared 36185.41%.
- Tracing PTN's Cash from Financing Activities over 5 years: stood at $9.8 million in 2022, then tumbled by 49.2% to $5.0 million in 2023, then slumped by 32.05% to $3.4 million in 2024, then soared by 433.3% to $18.0 million in 2025, then sank by 99.23% to $138878.0 in 2026.
- The last three Cash from Financing Activities figures came in at $138878.0 (Q1 2026), $18.0 million (Q4 2025), and $328200.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 138,878.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138,878.00 |
| Mar 31, 2026 | 138,878.00 |
| Dec 31, 2025 | 18.02 Mn |
| Dec 31, 2025 | 18.02 Mn |
| Sep 30, 2025 | 328,200.00 |
| Sep 30, 2025 | 328,200.00 |
| Jun 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 4.46 Mn |
| Mar 31, 2025 | 4.46 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | -126,969.00 |
| Sep 30, 2024 | -126,969.00 |
| Jun 30, 2024 | 5.99 Mn |
| Jun 30, 2024 | 5.99 Mn |
| Mar 31, 2024 | 9.14 Mn |
| Mar 31, 2024 | 9.14 Mn |
| Dec 31, 2023 | 4.97 Mn |
| Dec 31, 2023 | 4.97 Mn |